| __timestamp | Alnylam Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 24419536 |
| Thursday, January 1, 2015 | 60610000 | 34718089 |
| Friday, January 1, 2016 | 89354000 | 40998209 |
| Sunday, January 1, 2017 | 199365000 | 32022880 |
| Monday, January 1, 2018 | 382359000 | 19110051 |
| Tuesday, January 1, 2019 | 479005000 | 26556257 |
| Wednesday, January 1, 2020 | 588420000 | 52275890 |
| Friday, January 1, 2021 | 620639000 | 80981000 |
| Saturday, January 1, 2022 | 770658000 | 124431000 |
| Sunday, January 1, 2023 | 795646000 | 90932000 |
| Monday, January 1, 2024 | 975526000 | 98761000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Alnylam Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc. have taken different paths in this regard. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive growth strategy. In contrast, Arrowhead maintained a more conservative approach, with expenses increasing by approximately 270% over the same period.
Alnylam's peak in 2023, with expenses nearing $796 million, underscores its commitment to expansion, albeit at a high cost. Meanwhile, Arrowhead's expenses, peaking at $124 million in 2022, suggest a more measured approach. This divergence highlights the strategic choices companies face in balancing growth with cost efficiency. As the biotech landscape evolves, these strategies will play a pivotal role in shaping their future trajectories.
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
Comparing SG&A Expenses: Incyte Corporation vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Catalent, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Verona Pharma plc and Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.